Abstract：
OBJECTIVE: Ovarian cancer can be categorized into distinct histologic subtypes with varying identifiable risk factors, molecular composition, clinical features, and treatment. The global incidence of ovarian cancer subtypes remains limited, especially in low- and middle-income countries (LMICs) without high-quality cancer registry systems.
METHODS: We used data from population-based cancer registries of the Cancer Incidence in Five Continents project to calculate the proportions of serous, mucinous, endometrioid, clear cell, and other histologic subtypes of ovarian cancer. Proportions were applied to the estimated numbers of patients with ovarian cancer from Global Cancer Observatory 2020. Age-standardized incidence rates were calculated.
RESULTS: Globally, an estimated 133,818 new patients of serous cancer, 35,712 new patients of mucinous cancer, 29,319 new patients of endometrioid cancer, and 17,894 new patients of clear cell cancer were identified in 2020. The distribution of ovarian cancer histologic subtypes exhibited regional variation. Eastern Europe had the highest rate of serous and mucinous carcinomas, whereas Northern Africa and Eastern Asia had the highest burden of endometrioid and clear cell carcinomas, respectively.
CONCLUSIONS: This study provides a global incidence landscape of histologic subtypes of ovarian cancer, particularly in LMICs lacking comprehensive registry systems. Our analysis offers valuable insights into disease burden and guidance for tailored strategies for prevention of ovarian cancer.
METHODS: We used data from population-based cancer registries of the Cancer Incidence in Five Continents project to calculate the proportions of serous, mucinous, endometrioid, clear cell, and other histologic subtypes of ovarian cancer. Proportions were applied to the estimated numbers of patients with ovarian cancer from Global Cancer Observatory 2020. Age-standardized incidence rates were calculated.
RESULTS: Globally, an estimated 133,818 new patients of serous cancer, 35,712 new patients of mucinous cancer, 29,319 new patients of endometrioid cancer, and 17,894 new patients of clear cell cancer were identified in 2020. The distribution of ovarian cancer histologic subtypes exhibited regional variation. Eastern Europe had the highest rate of serous and mucinous carcinomas, whereas Northern Africa and Eastern Asia had the highest burden of endometrioid and clear cell carcinomas, respectively.
CONCLUSIONS: This study provides a global incidence landscape of histologic subtypes of ovarian cancer, particularly in LMICs lacking comprehensive registry systems. Our analysis offers valuable insights into disease burden and guidance for tailored strategies for prevention of ovarian cancer.
摘要：
目的：卵巢癌可以分为不同的组织学亚型，具有不同的可识别的危险因素，分子组成，临床特征,和治疗。卵巢癌亚型的全球发病率仍然有限，特别是在没有高质量癌症登记系统的低收入和中等收入国家（LMICs）。
方法：我们使用来自五大洲癌症发病率项目的基于人群的癌症登记数据来计算浆液的比例，粘液，子宫内膜样,透明细胞,和其他组织学亚型的卵巢癌。比例适用于2020年全球癌症观察站估计的卵巢癌患者人数。计算年龄标准化的发病率。
结果：全球，估计有133,818名浆液性癌新患者，35,712例黏液性癌新患者,29,319例子宫内膜样癌新患者，2020年，发现了17894名新的透明细胞癌患者。卵巢癌组织学亚型的分布表现出区域差异。东欧的浆液性癌和粘液性癌发生率最高，而北非和东亚的子宫内膜样癌和透明细胞癌负担最高，分别。
结论：这项研究提供了卵巢癌组织学亚型的全球发病率，特别是在缺乏全面登记制度的低收入国家。我们的分析为疾病负担提供了宝贵的见解，并为预防卵巢癌的量身定制策略提供了指导。
方法：我们使用来自五大洲癌症发病率项目的基于人群的癌症登记数据来计算浆液的比例，粘液，子宫内膜样,透明细胞,和其他组织学亚型的卵巢癌。比例适用于2020年全球癌症观察站估计的卵巢癌患者人数。计算年龄标准化的发病率。
结果：全球，估计有133,818名浆液性癌新患者，35,712例黏液性癌新患者,29,319例子宫内膜样癌新患者，2020年，发现了17894名新的透明细胞癌患者。卵巢癌组织学亚型的分布表现出区域差异。东欧的浆液性癌和粘液性癌发生率最高，而北非和东亚的子宫内膜样癌和透明细胞癌负担最高，分别。
结论：这项研究提供了卵巢癌组织学亚型的全球发病率，特别是在缺乏全面登记制度的低收入国家。我们的分析为疾病负担提供了宝贵的见解，并为预防卵巢癌的量身定制策略提供了指导。
